Effects of cryptoporus polysaccharide on rat allergic rhinitis associated with inhibiting eotaxin mRNA expression.
Aqueous extract from the fruiting body of Cryptoporus volvatus has been reported to present anti-tumor, anti-allergy, anti-inflammation and immunomodulatory activities. However, the effect mechanisms of anti-allergy and anti-inflammation are poorly understood. The aim of study is to evaluate whether Cryptoporus polysaccharides (CP) extracted from fruiting body of Cryptoporus volvatus decrease the development of nasal symptoms, airway hyperresponsiveness (AHR) to methacholine (MCh) and the infiltration of eosinophils in nasal mucosa in rat model of allergic rhinitis, and investigate a possible action mechanism of CP by detecting the expression of eotaxin mRNA in nasal mucosa and lung tissues. Rats were immunized with ovalbumin and consecutive topical antigen instillation was performed. Repeated intranasal ovalbumin challenge caused rhinitis symptom, AHR to MCh, eosinophil infiltration and histological alterations into the nasal mucosa and increase of eotaxin mRNA expression in nasal mucosa and lung tissue were examined. Pretreatment with CP 3, 9 and 27 mg kg(-1) (ig) decreased the numbers of sneezing 27.4%, 38.4% and 44.3% and nasal rubbing 27.5%, 34.9% and 47.7% comparison with model group, respectively. CP caused a dose-related inhibition of MCh-induced AHR. CP 27 mg kg(-1) decreased the expression of eotaxin mRNA in the nasal mucosa by 35%. These results suggest CP can relieve the symptom, eosinophil infiltration and injury of tissue in nasal mucosa and lung tissue and AHR of allergic rhinitis in rats. Its action mechanism may be associated with the decrease of eotaxin mRNA expression.
Xie
Qiang-Min
QM
Medical School of Zhejiang University, Hnagzhou 310031, China. xieqm@zju.edu.cn
Deng
Jun-Fang
JF
Deng
Yang-Mei
YM
Shao
Chuan-Sen
CS
Zhang
Hui
H
Ke
Chuan-Kui
CK
D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D018926:Anti-Allergic Agents / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D016535:Bronchial Hyperreactivity / Q000517:prevention & control; D001985:Bronchial Provocation Tests; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000235:genetics / Q000378:metabolism*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D004195:Disease Models, Animal; D004804:Eosinophils / Q000187:drug effects; D048690:Fruiting Bodies, Fungal / Q000737:chemistry; D005786:Gene Expression Regulation / Q000187:drug effects; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008170:Lung Compliance / Q000187:drug effects; D016210:Methacholine Chloride; D009297:Nasal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010047:Ovalbumin / Q000276:immunology; D011124:Polyporaceae / Q000737:chemistry*; D011134:Polysaccharides / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*
D018926:Anti-Allergic Agents; C515458:Ccl11 protein, rat; D054413:Chemokine CCL11; D019742:Chemokines, CC; D011134:Polysaccharides; D012333:RNA, Messenger; D016210:Methacholine Chloride; D010047:Ovalbumin